Physician profile
Daniel Blachman
NPI 1083931075
$14,664.50
in general payments reported to CMS, 2019-2025
34 companies · $2,033 in 2025
The $2,033 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,116 · 2020: $1,955 · 2021: $2,548 · 2022: $1,801 · 2023: $2,265 · 2024: $1,947 · 2025: $2,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,209 · Education: $36.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,209.01 |
| Education | $36.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,604.08 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,361.85 | 2019-2024 | Trulance |
| Janssen Biotech, INC. | $1,591.33 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $935.16 | 2019-2025 | |
| Gilead Sciences, INC. | $765.31 | 2019-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $532.33 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $303.60 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $278.52 | 2019-2022 | |
| Ardelyx, INC. | $234.06 | 2022-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $192.55 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $174.71 | 2019-2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $171.49 | 2019-2025 | |
| Celgene Corporation | $152.87 | 2021-2023 | Zeposia |
| Romark Laboratories, Lc | $143.06 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $125.25 | 2020-2023 | Linzess |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $120.90 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $117.30 | 2023 | |
| Janssen Scientific Affairs, LLC | $108.80 | 2019 | |
| Braintree Laboratories, INC. | $106.92 | 2019-2023 | Sutab, Suflave |
| Redhill Biopharma INC. | $100.77 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $83.78 | 2019-2024 | Clenpiq, Rebyota |
| Allergan, INC. | $80.82 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $63.46 | 2024-2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $52.45 | 2025 | Voquezna |
| Exact Sciences Corporation | $45.65 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boston Scientific Corporation | $36.48 | 2021-2022 | |
| Celltrion USA INC. | $36.15 | 2024-2025 | Zymfentra, Vegzelma |
| Concordia Pharmaceuticals INC. | $29.68 | 2019 | |
| Organon LLC | $23.93 | 2023 | Hadlima, Renflexis |
| Madrigal Pharmaceuticals | $20.66 | 2025 | Rezdiffra |
| Shionogi INC | $20.07 | 2020 | |
| Acacia Pharma INC | $19.95 | 2021 | |
| Ucb, INC. | $16.16 | 2019 | |
| Alfasigma USA, INC. | $14.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Blachman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.